Long-term experience with testosterone replacement through scrotal skin

[1]  Zhiling Yu,et al.  Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application , 1997, Journal of clinical pharmacology.

[2]  A. Dobs,et al.  Testosterone replacement treatment options for HIV-infected men. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[3]  Zhiling Yu,et al.  Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men , 1997, Journal of clinical pharmacology.

[4]  A. von Eckardstein,et al.  Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a). , 1997, The Journal of clinical endocrinology and metabolism.

[5]  T. Link,et al.  Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. , 1997, The Journal of clinical endocrinology and metabolism.

[6]  W. Jordan.  Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. , 1997, American journal of contact dermatitis : official journal of the American Contact Dermatitis Society.

[7]  W. Waldhäusl,et al.  Determination of testosterone production rates in men and women using stable isotope/dilution and mass spectrometry. , 1997, The Journal of clinical endocrinology and metabolism.

[8]  R. Casaburi,et al.  Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. , 1997, The Journal of clinical endocrinology and metabolism.

[9]  S. Arver,et al.  Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. , 1997, Urology.

[10]  A. Guccione,et al.  Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. , 1996, The Journal of clinical endocrinology and metabolism.

[11]  A. Dobs,et al.  Transdermal testosterone delivery systems , 1996 .

[12]  W. Zgliczyński,et al.  Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. , 1996, Atherosclerosis.

[13]  E. Nieschlag,et al.  Prostate volume in testosterone‐treated and untreated hypogonadal men in comparison to age‐matched normal controls , 1994, Clinical endocrinology.

[14]  M. Pandian,et al.  Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. , 1993, Fertility and sterility.

[15]  C G Brook,et al.  The relationship between endogenous testosterone and gonadotrophin secretion , 1993, Clinical Endocrinology.

[16]  J. S. Tenover,et al.  Effects of testosterone supplementation in the aging male. , 1992, The Journal of clinical endocrinology and metabolism.

[17]  S. Bhasin.  Clinical review 34: Androgen treatment of hypogonadal men. , 1992, The Journal of clinical endocrinology and metabolism.

[18]  L. Lantinga,et al.  Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. , 1991, The Journal of urology.

[19]  H. Ghusn,et al.  Evaluation and Treatment of Androgen Deficiency in Males , 1991 .

[20]  E. Nieschlag,et al.  Testosterone: Action, Deficiency, Substitution , 1990 .

[21]  A. Spiekerman,et al.  Prostatic complications of testosterone replacement therapy. , 1989, Archives of internal medicine.

[22]  J. Thornby,et al.  Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. , 1989, JAMA.

[23]  J. Findlay,et al.  Treatment of primary hypogonadism in men by the transdermal administration of testosterone. , 1989, The Journal of clinical endocrinology and metabolism.

[24]  M. Vance,et al.  Transdermal testosterone treatment of hypogonadal men. , 1988, The Journal of urology.

[25]  K. Langer,et al.  Substitution therapy of hypogonadal men with transdermal testosterone over one year. , 1988, Acta endocrinologica.

[26]  R. Santen,et al.  Transdermal testosterone therapy in the treatment of male hypogonadism. , 1988, The Journal of clinical endocrinology and metabolism.

[27]  J. Findlay,et al.  Transdermal delivery of testosterone. , 1987, The Journal of clinical endocrinology and metabolism.

[28]  E. Nieschlag,et al.  TRANSDERMAL TESTOSTERONE SUBSTITUTION THERAPY FOR MALE HYPOGONADISM , 1986, The Lancet.

[29]  L. Gooren.  Long-term safety of the oral androgen testosterone undecanoate. , 1986, International journal of andrology.

[30]  P. Snyder,et al.  Treatment of male hypogonadism with testosterone enanthate. , 1980, The Journal of clinical endocrinology and metabolism.

[31]  T. Ito,et al.  The source of plasma dihydrotestosterone in man. , 1971, The Journal of clinical investigation.

[32]  W. Collins,et al.  Androgen Metabolism in Human Skin , 1971, Proceedings of the Royal Society of Medicine.

[33]  M. A. Lesser.  Testosterone propionate therapy in one hundred cases of angina pectoris. , 1946, The Journal of clinical endocrinology and metabolism.

[34]  S. Bhasin,et al.  Emerging Issues in Androgen Replacement Therapy , 1997 .

[35]  F. Yates,et al.  Transdermal testosterone replacement through genital skin , 1990 .

[36]  E. Nieschlag,et al.  Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. , 1976, Hormone research.

[37]  R. Scheuplein,et al.  Percutaneous absorption of steroids. , 1969, The Journal of investigative dermatology.